Correction to: The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Nephrol Dial Transplant
.
2024 Mar 27;39(4):724.
doi: 10.1093/ndt/gfad252.
PMID:
38033315
PMCID:
PMC10966322
DOI:
10.1093/ndt/gfad252
No abstract available
Publication types
Published Erratum